Description:
The module provides a thorough review of current best practices, primary literature and national guideline recommendations for the supportive treatment of cancer patients.  The design or adjustment of patient specific pharmacotherapeutic plans including the incorporation of newer therapies for chemotherapy-induced nausea and vomiting will be described.  Optimization of the supportive care of cancer patients including anticoagulation and pain management will also be included in this module.  

• GI Complications
  • Constipation, diarrhea, mucositis, and chemotherapy-induced nausea and vomiting
• Anti-coagulation for cancer patients
  • Prevention and treatment of cancer-related venous thromboembolic disease
• Pain and palliative care

Learning Objectives:

1. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of GI complications, anti-coagulation, pain, and palliative care in cancer patients
2. Recognize the mechanisms of action, administration methods, common toxicities and monitoring parameters associated with medications used in the supportive care of patients with cancer
3. Select appropriate therapeutic interventions for the management of pain and other symptoms requiring palliation in cancer patients
4. Identify current literature and guideline recommendations for the management of complications of cancer or cancer therapy such as gastrointestinal complications and venous thromboembolic disease

Speaker: Morgan Culver, PharmD, BCOP

Disclosure: Morgan Culver - No financial relationships exist with commercial interests.

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-024-H01-P.

Activity Type: Application

 

 

Description:
Hematology/oncology pharmacists play a crucial role in the decision making and management of cancer therapy complications. The Supportive Care II module will focus on the management of hematology/oncology patients and the associated complications, including neutropenia, infectious complications, and the use of growth factors as primary and secondary prophylaxis. Additionally, learners will expect to identify the clinical presentation, management of bone health in patients with cancer as well as the oncologic emergencies: SVC syndrome, spinal cord compression, TLS, and hypercalcemia of malignancy.

This module will meet the educational needs of oncology pharmacists who care for cancer patients through the identification of cancer complications. The module will also discuss the treatment options for these patients.

Learning Objectives:

1. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of select oncologic emergencies including: superior vena cava syndrome, spinal cord compression, tumor lysis syndrome, and hypercalcemia of malignancy
2. Identify the appropriate use of growth factors in patient with cancer undergoing treatment
3. Interpret current literature and guideline recommendations for the optimal prevention and management of infections, febrile neutropenia, and other infectious complications in patients with cancer
4. Select appropriate therapeutic interventions for the management of bone health in patients with cancer

Speaker: Anne McDonnell, PharmD, BCOP

Disclosure: Anne McDonnell- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-025-H01-P.

Activity Type: Application

 

 

Description:
This module provides a review of common pediatric malignancies and explores therapeutic, monitoring, and preventative considerations pertinent to the role of pharmacotherapy specialists practicing in pediatric oncology. This module is developed to advance the clinical knowledge and decision-making skills of oncology pharmacists with regards to common malignancies that affect the pediatric population and the unique survivorship concerns that are faced within this patient population.

Learning Objectives:

1. Identify the etiology, pathophysiology, clinical presentation, and prognosis of common pediatric malignancies
2. Choose an individualized therapeutic plan based on an assessment of patient information, available evidence, and treatment guidelines for common pediatric malignancies
3. Compare expected outcomes of given therapeutic modalities (e.g. response, toxicity, survival, etc.) for common pediatric malignancies
4. Recognize prevention, monitoring, and treatment plans for long-term toxicity associated with the treatment of pediatric malignancies

Speaker: Diana Wu, PharmD, BCOP, BCPS

Disclosure: Diana Wu- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-041-H01-P.

Activity Type: Application

 

 

Description:
It has been demonstrated in the literature that 30-50% of all cancer cases are preventable with prevention offering the most cost-effective long-term strategy for cancer prevention and control. As a result, many national organizations, including WHO, NCI, ACS, AICR, USPSTF, ASCO and NCCN, have increased awareness of cancer causes and increased the focus on cancer screening and prevention. It is important for health care providers to know what the guidelines recommend as well as how to keep up with the changing technology available to them. The goals of this module will be to outline the various modifiable and non-modifiable risk factors for cancer, discuss pharmacologic and non-pharmacologic prevention methods and review the guidelines for early detection where they exist.

Learning Objectives:

1. Outline the various modifiable and non-modifiable risk factors associated with the multitude of oncologic malignancies
2. Use available data to provide recommendations for various pharmacologic and non-pharmacologic interventions in cancer prevention
3. Differentiate cancer screening recommendations from national guidelines for general versus high-risk populations

Speaker: Robert Mancini, PharmD, BCOP

Disclosure: Robert Mancini- Takeda- Speaker Bureau - Honoraria

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hours (.10 CEUs) under the ACPE universal activity number 0465-0000-20-026-H01-P.

Activity Type: Application

  

 

Description:
Due to the expanding data in understanding molecular targeted pathways and precision medicine in the field of oncology, oncology pharmacists need to be aware of the history of genomically guided therapy and the development of future targeted therapies. This module will educate oncology pharmacists on the role of molecular pathways in cancer development, the role of pharmacogenomics in cancer care, and assess novel advances in targeted therapeutics.

Learning Objectives:

1. Recognize the clinical significance of germline and somatic mutations found by utilizing next generation sequencing (NGS) techniques in patients with cancer
2. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of a patient with metastatic disease given results from a NGS panel.
3. Apply recent advances in the understanding of molecular pathways and genomic analysis to patients with relapse or refractory cancers.

Speaker: Jennifer Godden

Disclosure:  Jennifer Godden-Genome Medical- Consultant - Salary

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-023-H01-P.

Activity Type: Application

 

 

Description:
This module will focus upon all aspects of the Practice Management section of the BCOP examination.  Upon completion of this module, learners will have an understanding of the medication use process for hazardous drugs.  Learners will also be informed on key considerations as a practice leader in oncology pharmacy.

Learning Objectives:

1. Understand the guidelines and practice standards from professional organizations for the safe handling and administration of hazardous drugs
2. Compare the national accreditation and federal regulatory organizations requirements on the use of hazardous drugs in the care of cancer patients
3. Recall important components of medication purchasing and reimbursement as well as the other key considerations to manage health care cost effectiveness
4. Examine policies and procedures needed to support the financial needs of the cancer patient, such as patient assistance programs and compassionate use
5. Analyze the role technology and systems can contribute to best practices around safety and quality for the cancer patient

Speaker: Marc Earl, PharmD, BCOP

Disclosure: : Marc Earl - No financial relationships exist with commercial interests.

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2 contact hours (.20 CEUs) under the ACPE universal activity number 0465-0000-20-042-H01-P.

Activity Type: Application

 

Description:
This module will cover the different study designs used in oncology clinical trials, including both observational and investigational designs. Different aspects of study methodology will be discussed, including internal/external validity, endpoints, and statistical analyses. This module will also discuss an overview of the FDA drug approval process and regulations pertaining to oncology research.

Learning Objectives:

1. Recognize the different types of study designs used in oncology clinical trials
2. Choose appropriate clinical trial endpoints and statistical analyses based on the purpose of the study
3. Interpret the results of a clinical trial
4. Apply the results of a clinical trial to a patient based on the internal and external validity of the trial
5. Recall the FDA approval processes for drugs and biologics

Speaker: Sherrill Brown, PharmD, DVM, BCPS

Disclosure: Sherrill Brown- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2 contact hours (.20 CEUs) under the ACPE universal activity number 0465-0000-20-043-H01-P.

Activity Type: Application

 

 

Description:
Progress in the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) was stagnant for decades until the past few years, with multiple agents gaining U.S. Food and Drug Administration (FDA) approval. This module will focus on the pathophysiology, risk stratification, and current treatment of AML, ALL, and MDS, including the role of more recently FDA-approved agents in clinical practice. Upon completion, the learner will have knowledge of the current management of AML, ALL, and MDS, including the incorporation of the newer agents into guidelines and current practice standards.

Learning Objectives:

1. Outline the current risk stratification systems for myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).
2. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of AML, ALL, or MDS.
3. List significant patient counseling points for MDS, AML, and ALL therapies.

Speaker: Bernard Marini, PharmD, BCOP

Disclosure: Bernie Marini- Servier- Consultant - Honoraria, Astellas - Consultant - Honoraria

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-027-H01-P.

Activity Type: Application

  

 

Description:
This module will review the clinical management of chronic leukemias, namely chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML) and hairy cell leukemia (HCL). The use of oral small molecule inhibitors in both the front-line and relapsed/refractory settings for CLL will be covered. Small molecule inhibitors for CLL have unique toxicity profiles and special considerations for use that require a multidisciplinary, patient-centered approach.  Oral therapies remain the backbone of CML management as well.  This module will highlight the important role oncology pharmacists may have in treatment selection, adherence, and toxicity monitoring for these patient populations.

Learning Objectives:

1. Choose an individualized therapeutic plans based on the assessment of patient information, available evidence and treatment guidelines for the management of chronic leukemias
2. Determine the appropriate response to genomic test results in a patient with chronic leukemias
3. Select a plan for preventing, monitoring, and managing adverse reactions associated with pharmacotherapy for the treatment of chronic leukemias

Speaker: Alison Duffy, PharmD, BCOP

Disclosure: Alison Duffy- Pharmacy Times- Speaker Bureau - Honoraria, Amgen- Speaker Bureau - Honoraria

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hours (.10 CEUs) under the ACPE universal activity number 0465-0000-20-031-H01-P.

Activity Type: Application

  

 

Description:
This module will cover the key basics of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) and the role of HSCT in treating hematologic malignancies and select solid tumors. Topics covered will include stem cell source, mobilization, conditioning regimen intensity and agents utilized, and management of short and long-term complications including graft-versus-host disease (GVHD), infectious complications, and adverse effects of chemotherapy. The role of haploidentical HSCT, outpatient HSCT management, novel agents for GVHD treatment and infection prophylaxis, and the role of post-HSCT maintenance therapy will be highlighted given the increasing use in practice and recent FDA approvals.

Learning Objectives:

1. Distinguish the differences between available donor types, stem cell sources, and conditioning regimen intensity used in HSCT
2. Identify dose‐limiting toxicities associated with HSCT conditioning regimens and appropriate management strategies
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the prevention and management of acute graft-versus-host disease (GVHD), chronic GVHD, and infections typically observed in the HSCT population

Speaker: Katie Gatwood, PharmD, BCOP

Disclosure: Katie Gatwood- Incyte- Advisory Board Member - Honoraria, Heron Therapeutics- Advisory Board Member - Honoraria, Jazz Pharmaceuticals- Speaker Bureau - Honoraria

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hours (.10 CEUs) under the ACPE universal activity number 0465-0000-20-035-H01-P.

Activity Type: Application

  

 

Description:
This module will review the pathophysiology, clinical presentation, diagnosis/staging, and treatments for patients with newly diagnosed and relapsed/refractory lymphoma. This module will also focus on applying relevant literature to provide recommendations on the treatment of lymphoma. Patient cases will be used to demonstrate clinical pearls that are pertinent to caring for patients undergoing lymphoma treatment.

Learning Objectives:

1. Recognize differences in the pathophysiology and biology of lymphomas
2. Predict the prognosis of a patient with lymphoma based on clinical presentation, stage, and/or patient-specific factors
3. Identify appropriate supportive care interventions for lymphoma treatment regimens
4. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of lymphoma

Speaker: Brandon Shank, PharmD, BCOP

Disclosure: Brandon Shank- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-038-H01-P.

Activity Type: Application

  

 

Description:
This module will review and discuss the pathophysiology and epidemiology of multiple myeloma (MM), factors influencing treatment selection, symptom management, and supportive care. This module will also provide an in depth review of the hallmark clinical trials, efficacy and safety, monitoring, adherence and compliance, and sequencing of therapies. Oncology pharmacists play an integral role in the management of patients with MM and should be knowledgeable of management strategies to ensure optimal outcomes.

Learning Objectives:

1. Recognize the pathophysiology, etiology, clinical symptoms, cytogenetic aberrations, and epidemiology of multiple myeloma
2. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of multiple myeloma
3. Modify treatment and monitoring plans for patients with multiple myeloma in order to optimize safety, clinical outcomes, and adherence

Speaker: Kirollos Hanna, PharmD, BCOP, BCPS

Disclosure: Kirollos Hanna- Seattle Genetics- Advisory Board Member, Speaker Bureau, Consultant - Honoraria, Hyloris Pharmaceuticals- Consultant - Honoraria, Abbvie – Speaker Bureau - Honoraria, Taiho Oncology- Advisory Board Member - Honoraria, Rigel Pharmaceuticals- Advisory Board Member - Honoraria, Sandoz – Advisory Board Member - Honoraria, Incyte Corporation- Advisory Board Member - Honoraria, AstraZeneca- Advisory Board Member - Honoraria, Exelixis- Advisory Board Member - Honoraria, Astellas- Advisory Board Member - Honoraria, CVS- Stockholder, Employee

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hours (.10 CEUs) under the ACPE universal activity number 0465-0000-20-040-H01-P.

Activity Type: Application

  

 

Description:
Genitourinary cancers, including bladder, prostate, renal cell and testicular cancers, are commonly diagnosed in the United States. Although these cancers have in common their location within the urinary and/or male reproductive systems, they are very distinct cancers. This module will focus on the etiology, pathophysiology and molecular biology of bladder, prostate, renal cell and testicular cancers. Risk factors, modifiable and nonmodifiable, and appropriate prevention and screening recommendations for each cancer will be discussed. Optimal first and subsequent-line treatment options for each stage of these cancers will be examined, highlighting the supporting evidence and national treatment guideline recommendations. Additionally, toxicities of these regimens will be reviewed along with clinical and practical considerations for prevention and monitoring of these regimens from a patient-specific approach.

Learning Objectives:

1. Recognize the etiology, pathophysiology and molecular biology of bladder, prostate, renal cell and testicular cancers and the common complications of these cancers
2. Interpret patient-specific diagnostic information (ie, stage, pathology, molecular biomarkers) that dictate therapeutic decisions in bladder, prostate, renal cell and testicular cancers
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of bladder, prostate, renal cell and testicular cancers
4. Modify therapeutic plans based on patient-specific characteristics and toxicities due to treatment of bladder, prostate, renal cell and testicular cancers
5. Select appropriate prevention and monitoring strategies to address complications and toxicities and optimize treatment outcomes associated with treatment of bladder, prostate, renal cell and testicular cancers

Speaker: Lisa Holle, PharmD, BCOP

Disclosure: Lisa Holle- UCONN- Employee - Salary, HOPA Speaker Bureau - Honoraria, PRIME- Consultant - Honoraria, PHE Consultant - Salary, Honoraria, ISOPP- Principal Investigator - Grants

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2 contact hours (.20 CEUs) under the ACPE universal activity number 0465-0000-20-029-H01-P.

Activity Type: Application

  

 

Description:
This module will cover the management of breast cancer for BCOP exam preparation and recertification purposes. The module will review and update learners of epidemiology, genomic and molecular characteristics/targets, staging, treatment, and treatment toxicity management of breast cancer.

Learning Objectives:

1. Identify risk factors, staging, and prognosis of breast cancer
2. Recognize therapeutic targets for breast cancer based on genomic and molecular testing
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence, and treatment guidelines for the management of breast cancer
4. Modify therapeutic plans based on patient specific characteristics and toxicities due to treatment of breast cancer

Speaker: Neelam Patel, PharmD, BCOP

Disclosure: Neelam Patel- American Health Resources- Speaker Bureau - Honoraria

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-030-H01-P.

Activity Type: Application

  

 

Description:
The purpose of this module is to provide a comprehensive review of gynecologic malignances including ovarian, cervical, and endometrial cancer. Clinical and practical considerations from a patient-specific approach will also be discussed.

Learning Objectives:

1. Identify the key risk factors, epidemiology and pathophysiology related to the development of gynecological malignancies
2. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of gynecological malignancies
3. Modify therapeutic and monitoring plans based on patient-specific characteristics and toxicities due to the treatment of gynecological malignancies

Speaker: Shrina Patel, PharmD, BCOP

Disclosure: Shrina Patel- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hours (.10 CEUs) under the ACPE universal activity number 0465-0000-20-032-H01-P.

Activity Type: Application

 

 

Description:
Primary brain tumors are a heterogenous group of neoplasms arising from different cells within the central nervous system (CNS). Management varies based on histology and tumor classification by the World Health Organization (WHO).  Molecular parameters and patient specific factors, such as age, also affect treatment decisions.  This module will review epidemiology, pathophysiology, clinical features, classification and diagnosis of primary brain tumors. Current treatment guidelines and literature will be covered to identify the role of pharmacologic therapy in combination with radiation, surgery and medical devices for the management of primary brain tumors.

Learning Objectives:

1. Explain the pathophysiology and standard of care management of high-grade gliomas
2. Select an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of CNS Malignancies

Speaker: Samantha Reiss, PharmD, BCOP

Disclosure: Samantha Reiss- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 0.5 contact hours (.05 CEUs) under the ACPE universal activity number 0465-0000-20-034-H01-P.

Activity Type: Knowledge

 

 

Description:
Adult sarcomas encompass over 70 different subtypes but only account for 1% of all adult solid tumors. This module will include a broad overview of soft tissue sarcomas with a focus on the cytotoxic and targeted therapies. Literature will be evaluated and supportive care plans developed for specific therapies. This module will review how identifiable genetics help guide patient-specific treatment plans.

Learning Objectives:

1. Recognize the diagnosis, staging, and genetic markers associated with adult sarcomas
2. Select an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of adult sarcomas

Speaker: Christy Harris, PharmD, BCOP

Disclosure: Christy Harris- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 0.5 contact hours (.05 CEUs) under the ACPE universal activity number 0465-0000-20-028-H01-P.

Activity Type: Knowledge

 

 

Description:
Head and neck cancer (HNC) is a complex and heterogeneous group of cancers, representing the sixth most common cancer worldwide. As most patients often present with locally advanced disease, multi-modality treatment is typically required and may include surgery, radiation, and/or systemic therapy. Treatment for HNC is associated with significant acute and long-term toxicities, such as severe mucositis, odynophagia, dysphagia, emesis, and xerostomia. This module will discuss epidemiology, risk factors, and clinical presentation of HNC. It will also provide an overview of the treatment options for advanced and recurrent/metastatic HNC, including thyroid cancer.

Learning Objectives:

1. Recognize the epidemiology, pathophysiology, risk factors, clinical presentations, and staging for head and neck and thyroid cancers
2. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of head and neck and thyroid cancers
3. Prepare treatment and monitoring plans in order to optimize the management of short- and long-term complications related to the treatment of head and neck and thyroid cancers

Speaker: Linda Barnachea, PharmD, BCOP

Disclosure: Linda Barnachea- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hours (.10 CEUs) under the ACPE universal activity number 0465-0000-20-033-H01-P.

Activity Type: Application

 

 

Description:
This module will review and discuss the pathophysiology and epidemiology of gastrointestinal cancers, factors influencing treatment selection, symptom management, and supportive care. This module will also provide an in depth review of the hallmark clinical trials, efficacy and safety, monitoring parameters, and therapies used in the treatment of colorectal, pancreatic, gastric, esophageal, hepatocellular, and anal cancer.

Learning Objectives:

1. Interpret patient-specific diagnostic information (i.e., stage, pathology, molecular biomarkers) that dictate therapeutic treatment decisions in gastrointestinal malignancies
2. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of gastrointestinal cancers
3. Modify treatment and monitoring plans for patients with gastrointestinal cancers in order to optimize safety, clinical outcomes, and adherence
4. Identify management plans for the common toxicities associated with the treatment regimens frequently used to treat gastrointestinal cancers
5. Recognize common barriers to treatment in this population (i.e., difficulty swallowing, financial toxicity

Speaker: Allison Baxley, PharmD, BCOP

Disclosure: Allison Baxley- Exelixis- Advisory Board Member - Honoraria

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 2 contact hours (.20 CEUs) under the ACPE universal activity number 0465-0000-20-036-H01-P.

Activity Type: Application

  

 

Description:
Lung cancer is the second most common type of cancer behind breast cancer and prostate cancer.  However, it is the number one cause of cancer-related deaths even if breast, prostate, and colorectal cancer death rates were combined.  However, much progress has been made recently in form of screening, targeted therapy, and immunotherapies.  Understanding the pathophysiology and molecular markers have led to complex treatment combinations that have revolutionized the treatment of lung cancer.  This module will help provide clarity by reviewing the pathophysiology, risk factors, molecular targets, landmark clinical trials that have created current treatment guidelines, and adverse effects from treatments.  These tools will help the oncology pharmacist identify both the appropriate treatment and toxicity management strategies to help optimize treatment outcomes.

Learning Objectives:

1. Recognize how the pathophysiology, staging, and molecular markers of lung cancer impact treatment decision making
2. Interpret current literature and guideline recommendations to determine appropriate treatment options for the management of lung cancer
3. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of lung cancer
4. Identify appropriate therapeutic and monitoring plans based on patient-specific characteristics and toxicities due to the treatment of lung cancer

Speaker: Daniel Melzer, PharmD, BCOP

Disclosure: Daniel Melzer- Dedham Group- Consultant - Honoraria

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-037-H01-P.

Activity Type: Application

  

 

Description:
The treatment landscape for skin cancers continues to evolve with new indications and medications being added to treatment algorithms. With multiple immunotherapy agents and targeted therapies now approved throughout the spectrum of disease treatment, it is important for the oncology pharmacist to understand the similarities and differences in dosing, toxicity profiles, monitoring, and specific patient counseling pearls with these therapies. This module will review the study data and clinical considerations for the oncology pharmacist for the treatment of advanced melanoma and as well as discuss therapies approved for the treatment of non-melanoma skin cancers.

Learning Objectives:

1. Recall the treatment indications and dosing strategy for agents used in the management of melanoma and non-melanoma skin cancers
2. Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of melanoma and non-melanoma skin cancers
3. Modify a treatment algorithm for a patient with metastatic melanoma considering the patient’s mutational status, tolerability of therapy, and disease response

Speaker: Laura Alwan, PharmD, BCOP

Disclosure: Laura Alwan- Imedex- Speaker Bureau - Honoraria, Pharmacy Times Speaker Bureau - Honoraria, Clinical Care Options- Speaker Bureau - Honoraria, SGO Allied Health Meeting- Speaker Bureau - Meeting Registration, Housing

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hours (.10 CEUs) under the ACPE universal activity number 0465-0000-20-039-H01-P.

Activity Type: Application

  

 

Description:
This module will provide learners with a succinct yet comprehensive review of each major cytotoxic chemotherapeutic drug class. Information will detail mechanisms of action, mechanisms of resistance, pharmacokinetics, class and individual drug black box warning and adverse event profiles, as well as monitoring requirements.  Administration specifications, renal and/or hepatic dose adjustments, REMS program requirements, and risk of secondary malignancies will be reviewed. Lastly, important patient counseling points on administration, adverse events, and monitoring will be included.

Learning Objectives:

1. Recognize the mechanisms of action, mechanisms of resistance, pharmacokinetics, administration methods, common toxicities and monitoring parameters associated with the cytotoxic chemotherapy
2. Classify chemotherapeutic agents as cell cycle specific or non-specific
3. Identify which chemotherapeutic agents require renal and/or hepatic dose adjustments
4. State relevant counseling points for each chemotherapeutic agent

Speaker: Amber Clemmons, PharmD, BCOP

Disclosure: Amber Clemmons- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-019-H01-P.

Activity Type: Knowledge

 

Description:
This module will review mechanisms of action, mechanisms of resistance, pharmacokinetics and administration methods for a variety of targeted therapies, including small molecule inhibitors, monoclonal antibodies and antibody-drug conjugates.  Common toxicities, monitoring parameters and patient counseling points will also be covered.

Learning Objectives:

1. Recognize the mechanisms of action, mechanisms of resistance, pharmacokinetics, administration methods, common toxicities and monitoring parameters associated with targeted therapies
2. Outline requirements of REMS programs, where appropriate, with targeted therapies 
3. Recall availability and use of companion diagnostics for mutations associated with use of targeted therapies
4. Identify important patient counseling and education points for oncology patients receiving targeted therapies

Speaker: Meredith Moorman, PharmD, BCOP, CPP

Disclosure: Meredith Moorman- SPEC (Specialty Pharma Education Center)- Speaker Bureau - Honoraria

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-020-H01-P.

Activity Type: Knowledge

 

Description:
The immunotherapy module will review the mechanism of action, toxicities, dose adjustments, and important monitoring parameters of immunotherapy agents in the treatment of cancer patients.  Strategies to manage immune-related adverse events will be examined.  The role of patient selection will be discussed including the incorporation of PD-L1 receptor testing and the utilization of companion diagnostics.  Finally, essential information will be covered so the participant can effectively counsel patients on immunotherapy agents. 

Learning Objectives:

1. Recognize the mechanism of action, toxicities, and important monitoring parameters of immunotherapy agents
2. Select dose adjustments for immunotherapy in the setting of renal or hepatic impairment, or toxicities
3. Recall important counseling points including immunotherapy administration, toxicity management, and REMS considerations if applicable
4. Match immune-related adverse events with corresponding management strategies to optimize the use of immune checkpoint inhibitors in cancer patients

Speaker: Chris Campen, PharmD, BCOP

Disclosure: Chris Campen- Teva- Speaker Bureau - Honoraria, Amgen- Consultant - Honoraria, Coherus- Speaker Bureau - Honoraria

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.5 contact hours (.15 CEUs) under the ACPE universal activity number 0465-0000-20-021-H01-P.

Activity Type: Knowledge

 

Description:
This module will review the mechanism of action, dosing, pharmacokinetics, monitoring, adverse effects, and supportive care of endocrine therapies. Specific drug classes that will be discussed include Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Downregulators (SERD), Aromatase Inhibitors (AIs), Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonist, and Antiandrogens.  Patient counseling points on toxicities and monitoring will also be covered.

Learning Objectives:

1. Identify the mechanism of action and mechanism of resistance of the major classes of hormonal therapy
2. Recognize the dosing, pharmacokinetics, and adverse effects of hormonal therapy 
3. Select appropriate plans for monitoring and treating adverse effects of patients receiving hormonal therapy 

Speaker: Neha Mangini, PharmD, BCOP

Disclosure: Neha Mangini- No financial relationships exist with commercial interests

Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hours (.10 CEUs) under the ACPE universal activity number 0465-0000-20-022-H01-P.

Activity Type: Knowledge